IMMUNE-IMAGE
Specific Imaging of Immune Cell Dynamics using novel tracer strategies
Our vision is to set up a sustainable and flexible platform for molecular imaging of immune cell dynamics using novel tracer strategies. New immunotracers will enable smart monitoring of immunotherapies and widespread usage of a personalized medicine approach.
the Immune-Image newsletter!
Don’t you want to miss any information about the project like interviews with researchers, the latest news or events? Sign up for our newsletter! The newsletter is sent quarterly.
Background
Immunotherapies are revolutionising the treatment of many cancers and inflammatory diseases. However, immunotherapies are not always successful due to specific disease features in each patient and adaption of the immune system and the tumor during treatment. Therefore, there is an urgent clinical need to assess the immune status of individual patient and to regularly monitor the response to immunotherapy.
Main objective
Immune-Image will develop methods to visualize and study the immune cells involved before, during, and after immunotherapy, allowing selection of the right treatment for the right patient at the right time.
consortium
Immune-Image brings together 22 key stakeholders from across 9 countries. This consortium comprises 10 academic institutions, 4 SMEs, 1 patient organization and 7 pharmaceutical companies.
Latest news
PET Imaging: A powerful tool for the Immune-Image project
Positron Emission Tomography (PET), is a powerful imaging technique that allows researchers to study the activity of cells and tissues within the body. This imaging modality has been widely used in the medical field to diagnose and monitor a variety of diseases,...
Latest media
Scientist brochure
The Immune-Image project aims to develop and implement a novel non-invasive molecular imaging platform for assessing immune cell activation and dynamics in oncology and inflammatory diseases, both in animal models and in patients. If you would like to read more about...
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 831514. This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
